Abbott Laboratories Shares Face Investor Scrutiny After Mixed Results

Investors have applied significant pressure to Abbott Laboratories' stock following the release of its latest quarterly figures and a cautious outlook for the coming year. While the company's adjusted earnings per share provided a slight positive surprise, a revenue shortfall and a tempered EPS forecast were enough to unsettle the market. The equity's notable decline is primarily attributed to underperformance in its Nutrition and Diagnostics divisions.

The fourth quarter and full-year 2025 results presented a mixed financial picture for the healthcare giant.

Fourth Quarter 2025:
* Adjusted diluted earnings per share (EPS): $1.50, marginally ahead of the $1.49 consensus estimate.
* Revenue: $11.46 billion, falling short of the $11.8 billion analysts had anticipated and representing an unexpected top-line miss.

Full Year 2025:
* Total revenue reached $44.3 billion.
* Adjusted EPS came in at $5.15, marking a 10% year-over-year increase.

2026 Guidance:
Management projected organic sales growth between 6.5% and 7.5% for the full year 2026. The forecast for adjusted EPS is set in a range of $5.55 to $5.80. The midpoint of this EPS guidance sits slightly below current market consensus expectations.

The data indicates that while profitability metrics remain largely solid, concerns over revenue momentum are driving the negative investor sentiment.

Should investors sell immediately? Or is it worth buying Abbott Laboratories?

Key Drivers of the Stock's Decline

Two core business segments were identified as the main sources of weakness in the report.

1. Nutrition Segment: Sales declined by approximately 9% on both a reported and organic basis. Company leadership cited lower sales volumes and targeted pricing actions, noting that headwinds are expected to persist, particularly through the first half of 2026.
2. Diagnostics Segment: Performance in this division also softened. Abbott attributed this to a normalization in demand for COVID-19 tests and challenging market conditions in China.

In contrast, the Medical Devices unit continues to be a robust growth engine. Sales there advanced by 12.3% in Q4, fueled by strong performance of the FreeStyle Libre system and a recovery in electrophysiology procedures. Furthermore, recent regulatory approvals—including U.S. clearance for the Volt™ PFA System and a CE mark for the TactiFlex™ Duo—are anticipated to strengthen the device portfolio.

An additional factor weighing on investor minds is the planned acquisition of Exact Sciences, announced in November 2025. The transaction, expected to close in the second quarter of 2026, is designed to bolster Abbott's position in cancer diagnostics. However, it has raised near-term concerns regarding the acquisition premium and potential dilution effects.

The market movement reflects this complex set of factors. Shares closed Friday's session at €91.20. This price represents a one-week decline of roughly 12.5% and leaves the stock trading approximately 32% below its 52-week high.

Forward-Looking Considerations

In the near term, Abbott is likely to continue facing challenges within its Nutrition and Diagnostics businesses. Executives have indicated that a recovery in these areas is not anticipated until the latter half of 2026, supported by new product launches.

Market attention will now focus on several critical factors: the organic momentum across business units, the successful commercialization of newly approved devices, and the financial implications of the pending Exact Sciences acquisition. Investors will be closely monitoring revenue trends in the first two quarters of 2026, as well as specific details regarding the financing of the takeover.